Given recent FDA accelerated approval of pembrolizumab for MSI-H tumors regardless of site of origin, does it make sense to apply MSI testing, in...
New answer by Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida (May 25, 2017)
The accelerated approval of pembrolizumab in MSI-H tumors was based on data from 149 pateints with MSI-H or dMMR cancers from five different single arm studies. Ninety of thos...